Objective To investigate the diagnostic value of combined detection of monoclonal gastric cancer 7 antigen (MG7-Ag), gastrin-17 (G-17) and carbohydrate antigen 19-9 (CA19-9) for gastric cancer. Methods A retrospective analysis was conducted on 262 patients with gastric diseases admitted to Shuyang Hospital of traditional Chinese Medicine Affiliated to Medical College of Yangzhou University from January 1,2022 to January 1,2024, including 74 cases of chronic non-atrophic gastritis(28.25%), 62 cases of chronic atrophic gastritis(23.66%), 42 cases of gastric ulcer(16.03%), 43 cases of gastric intraepithelial neoplasia (16.41%), and 41 cases of gastric cancer(15.65%). Forty-one patients were randomly selected from each of the chronic non-atrophic gastritis, chronic atrophic gastritis, gastric intraepithelial neoplasia, and gastric cancer groups for further analysis. The differences in serum levels of MG7-Ag, G-17, and CA19-9 were illustrated. For different stages of disease progression, a binary logistic regression model was constructed for the combined diagnosis of the three indicators, and the predicted probability output by the model was used as the combined detection indicator. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic performance of individual and combined detection. Results The levels of MG7-Ag, G-17, and CA19-9 were significantly higher in the gastric cancer group than those in the precancerous lesion group, and the differences were statistically significant (P<0.05). In gastric cancer diagnosis, the combined test achieved an AUC of 0.970, significantly higher than the single test of MG7-Ag (0.909), G-17 (0.680), and CA19-9 (0.852) (P<0.05), with optimal sensitivity (97.6%) and specificity (87.8%). In precancerous lesion stages (chronic atrophic gastritis and intraepithelial neoplasia), although combined detection did not significantly increase the AUC value, it improved the overall performance of sensitivity and specificity. Conclusions The combined detection of MG7-Ag, G-17, and CA19-9 has high value in the diagnosis of gastric cancer, and its diagnostic efficacy is superior to that of individual indicators.
Key words
MG7-Ag /
G-17 /
CA19-9 /
diagnosis /
gastric cancer
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Li Y,Zhao Y,Li Y,et al.Gastrin-17 induces gastric cancer cell epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway[J].J Physiol Biochem,2021,77(1):93-104.
[2] Wang X D,Gao N N,Diao Y W,et al.Conjugation of toll-like receptor-7 agonist to gastric cancer antigen MG7-Ag exerts antitumor effects [J].World J Gastroenterol,2015,21(26):8052-8060.
[3] Smyth E C,Nilsson M,Grabsch H I,et al.Gastric cancer [J].Lancet,2020,396(10251):635-648.
[4] 田敬华,杨金玲,秦 杰,等.miR-34启动子甲基化在胃癌发病过程中的作用研究[J].分子诊断与治疗杂志, 2019,11(1):17-21.
[5] Haque E,Esmail A,Muhsen I,et al.Recent trends and advancements in the diagnosis and management of gastric cancer[J].Cancers (Basel),2022,14(22):5615.
[6] Roşu M C,Ardelean A,Moldovan S D,et al.The importance of CA 72-4 and CA 19-9 dosing in gastric cancer [J].J Med Life,2023,16(2):186-188.
[7] 张鹏飞,杨小飞,瞿 焱,等.血清MG7-Ag水平检测与新型胃癌评分系统在胃癌高危人群风险评估中的价值[J].现代肿瘤医学,2024,32(8):1458-1461.
[8] Wu S,Qu X,Wang N,et al.MG7-Ag, hTERT, and TFF2 identified high-risk intestinal metaplasia and constituted a prediction model for gastric cancer [J].Chin Med J (Engl),2023,136(5):610-612.
[9] Lin Z,Bian H,Chen C,et al.Application of serum pepsinogen and carbohydrate antigen 72-4 (CA72-4) combined with gastrin-17 (G-17) detection in the screening, diagnosis, and evaluation of early gastric cancer [J].J Gastrointest Oncol,2021,12(3):1042-1048.
[10] 吕文艳,刘佳乐,刘 航,等.早期胃癌患者化疗前后血清AFP、CEA、CA19-9、CA125水平变化及其对淋巴结转移的预测价值[J].海南医学,2024,35(1):100-104.
[11] Shen H,Xiong K,Wu X,et al.The diagnostic value of serum gastrin-17 and pepsinogen for gastric cancer screening in eastern China[J].Gastroenterol Res Pract,2021,2021:6894248.
[12] 房静远,刘文忠,李兆申,等.中国慢性胃炎共识意见(2012年,上海) [J].中国医学前沿杂志(电子版),2013, 5(7):44-55.
[13] Koemans W J,Kaaij R T,Sandick J W.Reply to correspondence to “treatment of peritoneal dissemination in stomach cancer patients with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): first results of the PERISCOPEI study” [J].Br J Surg,2021,108(2):e94-e97.
[14] 郑荣寿,陈 茹,韩冰峰,等.2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2024,46(3):221-231.
[15] Guo D L,Dong M,Wang L,et al.Expression of gastric cancer-associated MG7 antigen in gastric cancer, precancerous lesions and H. pylori -associated gastric diseases [J].World J Gastroenterol,2002,8(6):1009-1013.
[16] Liu J,Hu J L,Zhang X Y,et al.The value of MG7 antigen in predicting cancerous change in dysplastic gastric mucosa [J].Int J Clin Pract,2002,56(3):169-172.
[17] 雷海锋,寇振宇,闫 磊,等.胃癌组织中HuR表达与临床病理及生存状况的关系[J].局解手术学杂志,2019, 28(5):352-356.
[18] Wang Z,Mo T M,Tian L,et al.Gastrin-17 Combined with CEA, CA12-5 and CA19-9 improves the sensitivity for the diagnosis of gastric cancer [J].Int J Gen Med,2021,14:8087-8095.
[19] Shibata C,Nakano T,Yasumoto A,et al.Comparison of CEA and CA19-9 as a predictive factor for recurrence after curative gastrectomy in gastric cancer[J].BMC Surg,2022,22(1): 213-216.
PDF(1012 KB)
